What Is the Status of Regenerative Therapy in Heart Failure?

Devika Kir, Mausam J. Patel, Mrudula R. Munagala

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations


Purpose of Review: Heart failure remains a major public health concern with high burden of morbidity and mortality despite advances in pharmacotherapy, device therapy, and surgical and percutaneous techniques. Cardiac regeneration may have a role to play in these patients with a huge unmet need for these therapies in patients with chronic ischemic heart disease, post-infarct heart failure, dilated cardiomyopathy, and heart failure with preserved ejection fraction. Recent Findings: In this review, we focus on the pre-clinical and translational basis for different modes of cardiac regenerative medicine and then critically appraise the clinical evidence amassed from pivotal clinical trials focused on cardiac regeneration for ischemic and non-ischemic cardiomyopathies. Summary: Cardiac regenerative medicine is rapidly evolving with novel approaches involving cell-based, cell-free, tissue engineering, and hybrid therapies to achieve myocardial regeneration and repair. Further studies are warranted with a robust comparison arm with optimal contemporary medical therapy to translate regenerative therapies to a clinical reality.

Original languageEnglish (US)
Article number146
JournalCurrent Cardiology Reports
Issue number10
StatePublished - Oct 2021


  • Cardiac regeneration
  • Cardiomyopathy
  • Stem cells

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'What Is the Status of Regenerative Therapy in Heart Failure?'. Together they form a unique fingerprint.

Cite this